Stay updated with breaking news from Prolixin Tablets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Read more about Zydus Cadila receives USFDA approval for Fluphenazine Hydrochloride Tablets on Business Standard. Fluphenazine belongs to a class of medications called phenothiazines and is also referred to as a neuroleptic. The drug will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals
Dr. Reddy's Laboratories announces the launch of Fluphenazine Hydrochloride Tablets, USP in the U.S. Market
Dr Reddy's Laboratories along with its subsidiaries announced the launch of Fluphenazine Hydrochloride Tablets, USP, in the U.S. market. The company along with its subsidiaries today announced the launch of Fluphenazine Hydrochloride Tablets, USP, a therapeutic equivalent generic version of Prolixin Tablets, 1 mg, 2.5 mg, 5 mg, and 10 mg, approved by the U.S. Food and Drug Administration (USFDA). The Prolixin brand and generic had U.S. sales of approximately $134 million MAT for the most recent twelve months ending in December 2020 according to IQVIA Health. Dr Reddy's Fluphenazine Hydrochlo...
Dr. Reddy’s Laboratories (DRL) has introduced Fluphenazine Hydrochloride Tablets, USP, a drug indicated in the management of manifestations of psychotic disorders, in the U.S. market. Launched followi
Domestic indices declined for third consecutive trading session on selling pressure in index pivotals. The Nifty slipped below the 15,100 mark in intraday trade but managed to close above that level. Negative cues from Asian markets impacted sentiment. As per the provisional closing data, the barometer index, the S&P BSE Sensex, dropped 379.14 points or 0.73% at 51,324.07. The Nifty 50 index fell 89.95 points or 0.59% at 15,118.35. The broader market outperformed the benchmark indices. The S&P BSE Mid-Cap index rose 0.69% while the S&P BSE Small-Cap index gained 0.67%. The market breadth, in...